Just before the New Year Envisagenics announced a strategic collaboration agreement between Cancer Research Horizons and Queen Mary University of London where they will leverage its SpliceCore® AI platform.   Dynamk Capital portfolio companies like Alpenglow, BitBio, Curi Bio, & Envisagenics are developing next generation tools to accelerate drug discovery.

Hear Martin Akerman, Ph.D., Envisagenics’ CTO and Co-founder discuss the promise of AI in this short clip from our 2022 Annual General Meeting interview